Findings: Don’t blame patients for all inhaler-use errors; singing may help improve breathing, QOL; Rx adherence does improve over time; plus 3 more outcomes of interest.
Breathlessness Related to Medical Conditions in Middle-Aged Adults: Daily Dose
Your daily dose of the clinical news you may have missed.
Respiratory Tripledemic 2022-23: An Expert Recap
William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.
Tezepelumab for COPD Moves into Phase 3 Planning
Tezepelumab, a TSLP inhibitor, reduced COPD exacerbations in individuals with moderate/very severe COPD, regardless of baseline BEC and inflammatory drivers, Amgen said.
NAVIGATOR: Tezepelumab Reduces Asthma Exacerbations by More than Half
In our latest podcast episode, Njira Lugogo, MD, discusses NAVIGATOR data she presented at ATS 2022 that showed clinical responses to treatment with tezepelumab.
Breathlessness in Middle-Aged Adults Linked to Overweight/Obesity, Stress, and Respiratory Disease
Results of a recent study support the importance of lifestyle interventions to reduce the burden of breathlessness in middle-aged adults.
Pfizer: MONeT Study Topline Data Positive for Abrysvo in Adults Aged 18 to 59 Years at High Risk for RSV-LRTD
Pfizer plans to submit the phase 3 MONeT data to regulatory bodies in support of an expanded label for Abrysvo to include adults aged 18 to 59, the company said.